These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 36076888)

  • 1. Food and Gut Microbiota-Derived Metabolites in Nonalcoholic Fatty Liver Disease.
    Jeong MK; Min BH; Choi YR; Hyun JY; Park HJ; Eom JA; Won SM; Jeong JJ; Oh KK; Gupta H; Ganesan R; Sharma SP; Yoon SJ; Choi MR; Kim DJ; Suk KT
    Foods; 2022 Sep; 11(17):. PubMed ID: 36076888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis.
    Han H; Jiang Y; Wang M; Melaku M; Liu L; Zhao Y; Everaert N; Yi B; Zhang H
    Crit Rev Food Sci Nutr; 2023; 63(12):1689-1706. PubMed ID: 34404276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
    Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
    mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatty Liver Disease and Gut Microbiota: A Comprehensive Update.
    Campo L; Eiseler S; Apfel T; Pyrsopoulos N
    J Clin Transl Hepatol; 2019 Mar; 7(1):56-60. PubMed ID: 30944821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD.
    Jiang X; Zheng J; Zhang S; Wang B; Wu C; Guo X
    Front Med (Lausanne); 2020; 7():361. PubMed ID: 32850884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tectorigenin ameliorated high-fat diet-induced nonalcoholic fatty liver disease through anti-inflammation and modulating gut microbiota in mice.
    Duan R; Huang K; Guan X; Li S; Xia J; Shen M; Sun Z; Yu Z
    Food Chem Toxicol; 2022 Jun; 164():112948. PubMed ID: 35390440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of
    Wang T; Ishikawa T; Sasaki M; Chiba T
    Front Med (Lausanne); 2022; 9():822190. PubMed ID: 35308549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Microbiota and It's Correlation With Metabolites in the Gut of Mice With Nonalcoholic Fatty Liver Disease.
    Gu C; Zhou Z; Yu Z; He M; He L; Luo Z; Xiao W; Yang Q; Zhao F; Li W; Shen L; Han J; Cao S; Zuo Z; Deng J; Yan Q; Ren Z; Zhao M; Yu S
    Front Cell Infect Microbiol; 2022; 12():870785. PubMed ID: 35694542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms.
    Bakhshimoghaddam F; Alizadeh M
    Clin Nutr ESPEN; 2021 Aug; 44():61-68. PubMed ID: 34330514
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Yoon SJ; Yu JS; Min BH; Gupta H; Won SM; Park HJ; Han SH; Kim BY; Kim KH; Kim BK; Joung HC; Park TS; Ham YL; Lee DY; Suk KT
    Front Microbiol; 2023; 14():1129904. PubMed ID: 36937300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates.
    Khan A; Ding Z; Ishaq M; Bacha AS; Khan I; Hanif A; Li W; Guo X
    Int J Biol Sci; 2021; 17(3):818-833. PubMed ID: 33767591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary Intervention Reverses Fatty Liver and Altered Gut Microbiota during Early-Life Undernutrition.
    Bauer KC; Huus KE; Brown EM; Bozorgmehr T; Petersen C; Cirstea MS; Woodward SE; McCoy J; Hun J; Pamplona R; Ayala V; Finlay BB
    mSystems; 2020 Sep; 5(5):. PubMed ID: 32900869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
    Zhang X; Coker OO; Chu ES; Fu K; Lau HCH; Wang YX; Chan AWH; Wei H; Yang X; Sung JJY; Yu J
    Gut; 2021 Apr; 70(4):761-774. PubMed ID: 32694178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases.
    Park JW; Kim SE; Lee NY; Kim JH; Jung JH; Jang MK; Park SH; Lee MS; Kim DJ; Kim HS; Suk KT
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis.
    Quesada-Vázquez S; Aragonès G; Del Bas JM; Escoté X
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents.
    Tokuhara D
    Front Nutr; 2021; 8():700058. PubMed ID: 34250000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
    Chen J; Thomsen M; Vitetta L
    J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role and effective therapeutic target of gut microbiota in NAFLD/NASH.
    Liu Q; Liu S; Chen L; Zhao Z; Du S; Dong Q; Xin Y; Xuan S
    Exp Ther Med; 2019 Sep; 18(3):1935-1944. PubMed ID: 31410156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications.
    Chen J; Vitetta L
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32717871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.